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Pharmaceutical and personal care products have benefited humans and animals 
around the world. However, their presence in natural and treated water system as 
emerging contaminates may have potentially adverse effects on the aquatic environment 
and cause development of bacterial resistance. In this research project, a comprehensive 
liquid chromatography tandem mass spectrometry method has been developed and 
validated for the analysis of sixteen pharmaceutical compounds using solid phase 
extraction. Treated and untreated water samples collected across Missouri from water 
treatment facilities were analyzed to access the distribution of sixteen pharmaceutical 
compounds in both winter and summer seasons. The results of the occunence study 
indicated that these pharmaceutical compounds in different types of water resources were 
usually below 80 ng/L, except caffeine. It was also found that the treatment processes in 
water facilities were effective to remove pharmaceutical compounds in most cases. The 
study of pharmaceutical elimination is still crucial in providing information for the 
disinfection strategy in water treatment facilities. The follow-up study was performed to 
investigate both the treatability and elimination of eight detected pharmaceuticals in the 
occurrence study as a function of treatment approach, types of disinfections (free chlorine, 
monochloramine, ozone and permanganate ), and treatment conditions (e.g., pH, contact 
time, etc). The results indicated that the degradation levels of pharmaceutical compounds 
varied significantly in different oxidation processes. Chlorination at 1 mg/L was found to 
be highly effective in the elimination of the selected pharmaceuticals. The pH conditions 
also played an important role in pharmaceutical removal, and its effect was conditional 
based on the oxidation system and pharmaceutical involved. 
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1. INTRODUCTION 
Pharmaceuticals, hormones, and endocrine disruption compounds are widely used 
around world for the benefit to humans and animals. Recently, the detection of 
pharmaceuticals and personal care products (PPCPs) in various natural environmental 
water sources (often a result of municipal wastewater discharge), as well as treated 
drinking water (incomplete removal during water treatment process), has been 
increasingly reported. The presence of this group of compounds as emerging 
contaminates in natural and drinking water systems has attracted increasing public 
concerns about their potential adverse ecological effects on aquatic organism at trace 
levels, possible estrogenic or androgenic effects on human health, as well as the 
development of bacterial resistance. 
1.1. PHARMACEUTICALS AND PERSONAL CARE PRODUCTS 
Pharmaceuticals and personal care products (PPCPs) are a group of compounds 
consisting of over-the-counter (OTC) drugs, prescription drugs, drugs used exclusively in 
hospitals and active drug ingredients used in research area [1]. It is estimated that around 
3000 pharmaceutically active compounds are currently used in drug development [2]. 
PPCPs are generally made for a wide variety of applications to benefit humans 
and livestock. Due to their chemical properties, some compounds can be easily broken 
down in a human or animal body, or degraded in the environment. However, some 
pharmaceuticals are very resistant to disinfection treatment, bacterial or other natural 
conditions. Therefore, the pharmaceuticals that are stable in the environment can be 
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eventually transferred to drinking water systems and promote possible adverse effects on 
human health [3-5]. Even though the risk that trace amount of pharmaceuticals pose to 
humans is still under investigation, some studies found that the potential adverse effect 
from pharmaceuticals on the aquatic environment still exists [6-8]. For example, 
estrogenic effects including alteration of sex ratio and decreased egg fertilization in fish 
are quite possible from endocrine disruption compounds (ECDs) [9, 10]. 
1.2. ANALYTICAL TRENDS 
Research on pharmaceuticals has grown exponentially in the last several years 
(review 2010). The detection of pharmaceuticals in environmental samples usually 
employs liquid cluomatography-tandem mass spectrometry (LC-MS/MS) [4-5, 11-20] or 
Liquid cln·omatography-mass spectrometry (LC-MS) [21-23]. LC-MS is a more popular 
technique than GC-MS in analysis of pharmaceuticals because these compounds are 
usually highly polar [10]. Yet, efficient derivatization followed by gas chromatography-
mass spectrometly (GC-MS) or gas chromatography-tandem mass spectrometry (GC-
MS/MS) was also used [2, 9-1 0]. The detection limit of pharmaceutical measurement 
usually can fall at nanogram per liter levels in environmental samples after solid phase 
extraction (SPE) [10]. Most widely used LC interfaces coupled with mass spectrometry 
are electro-spray ionizaiotn (ESI) and atmospheric pressure chemical ionization (APCI) 
[2]. 
The presence of pharmaceuticals in many different types of natural surface water 
systems including rivers, lakes, and reservoirs has been increasingly repmied 
[3, 7, 24-34]. Due to the incomplete removal of pharmaceutical in drinking water 
treatment process, detection of pharmaceuticals in treated drinking water was reported as 
well [3, 35]. Currently, pharmaceutical compounds and hormones are listed on the US 
environmental protection agency's (US EPA) final contaminant candidate list (CCL)- 3 
[10, www.epa.gov/safewater/ccl]. 
1.3. PHARMACEUTICAL COMPOUND SELECTION 
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In this study, totaling sixteen pharmaceutical compounds were selected for 
occurrence study. The preliminary research indicated that some pharmaceutical 
compounds including caffeine, ibuprofen, and acetaminophen were detected in Missouri 
river water samples. In addition, these compounds were chosen to represent different 
groups of pharmaceutical compounds, including analgesics, antibiotics and antimicrobials, 
anticonvulsant/antiepileptics, antidiabetics, antihystamines, anti psychotics, 
antidepressants, antianxiety drugs, beta-blockers (~-blockers), cytostatics and 
antineoplastics, estrogens and hormonal compounds, lipid-regulators, stimulants, and X-
ray contrast media. Table I lists general information about these pharmaceutical 
compounds in this study. The structures of these pharmaceuticals are shown in Figure I. 
In order to make this study more representative, water sampling location were 
also carefully chosen. Water samples were taken from a broad range of resources, 
including rivers, reservoirs, lakes, unconsolidated wells, and deep wells. The difference 
of distribution among these water sources was also compared. 
Table 1.1 Selected phannaceutical compmmds and their general information. 
C OJ:q>OUDds Formula CAS# Molecular weight Class 
acetaminophen C 8H 9N02 103-90-2 15 1.2 analgestts 
caffeine CsH1oN402 58- 08- 2 194.2 stinm1ant 
carbamazepine C1 5H12N20 298-46- 4 236.3 anticonvulsant 
clofibric acid C 10H 11Cl03 8 82 - 09- 07 214.7 lipid-regulator 
codeine C1sH21N03 76-57- 3 299.4 analgestts 
estradiol C 1sH2402 50- 28-2 272.4 hormone 
estriol C1sH2403 50-27- 1 288.4 hormone 
estrone C1sH2202 53-16-7 270.4 hormone 
ethyny1estradiol C2oH2402 57-63- 6 296.4 hormone 
ibuprofen C 13H 180 2 15687-27-1 206.3 analgestts 
iopromide C1sH24I3N30s 107793-72-6 791.1 X-ray contrast media 
lincomycin C 18H 34N 20 6S 154-21-2 406.5 anttbiotics 
sulfamethoxa.znle C 10H 11N 30 3S 723 - 46-6 253.3 annbiotics 
tri;losan C 12H 7Cl30 2 3380- 34-5 289.5 antibiotics 
trimethoprim C14H1sN403 738-70-5 290.3 annbiotics 
tylosin C46H77N017 1401 - 69-0 916.1 antibiotics 
~ 
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1.4. ELIMINATION STRATEGIES 
It is known that pharmaceutical compounds are introduced to the environment as 
a result from incomplete removal in wastewater treatment. Reliable information for 
pharmaceutical elimination from source water is crucial to water treatment facilities. Free 
chlorine, ozone, and permanganate are very commonly used oxidants in the drinking 
water process. Monochloramine is a disinfectant often used in water treatment plants to 
prevent the growth of bacterial. Free chlorine and ozone were found to effectively 
remove pharmaceutical compounds [36-40]. Hydrogen peroxide was usually combined 
with ozone to work as an advanced oxidation method for pharmaceutical decomposition 
in some studies [ 41, 42]. Other chemical oxidations (permanganate, and chloramine) 
were reported [43, 44], however, not all pharmaceutical compounds were included. 
In this study, a LC-MS/MS method was developed and validated in tap and lab 
reagent water for analysis of sixteen pharmaceutical compounds in environmental water 
samples collected in the state of Missouri. Validation results indicated that this high 
throughput approach was accurate. The distribution of pharmaceutical compounds were 
obtained and compared in both cold and hot seasons. The results indicated that reliable 
information was needed for elimination of these compounds from drinking water. 
Treatability and elimination of pharmaceutical compounds that were found in the 
occurrence study by oxidation and PAC was then investigated. 
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1. Investigation of Phannaceuticals in Missouri Natural and Drinking 
Water Using High Performance Liquid Chromatography-Tandem Mass 
Spectrometry 
ABSTRACT 
A comprehensive method has been developed and validated in two different water 
matrices for the analysis of 16 pharmaceutical compounds using solid phase extraction 
(SPE) of water samples, followed by liquid chromatography coupled with tandem mass 
spectrometry. These 16 compounds include antibiotics, hormones, analgesics, stimulants, 
antiepileptics, and X-ray contrast media. Method detection limits (MDLs) that were 
determined in both reagent water and municipal tap water ranged from 0.1 to 9.9 ng/L. 
Recoveries for most of the compounds were comparable to those obtained using U.S. 
EPA methods. Treated and untreated water samples were collected from 3 1 different 
water treatment facilities across Missouri, in both winter and summer seasons, and 
analyzed to assess the 16 pharmaceutical compounds. The results showed that the highest 
pharmaceutical concentrations in untreated water were caffeine, ibuprofen, and 
acetaminophen, at concentrations of 224, 77.2, and 70 ng/L, respect ively. Concentrations 
of pharmaceuticals were generally higher during the winter months, as compared to those 
in the summer due, presumably, to smaller water quantities in the winter, even though 
pharmaceutical loadings into the receiving waters were similar for both seasons. 
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1. INTRODUCTION 
Many types of pharmaceuticals are used in this country for a wide variety of 
applications to benefit humans and animals. Impmtant classes of human pharmaceuticals 
include: analgesics, antibiotics and antimicrobials, anticonvulsant/antiepileptics, 
anti diabetics, antihystamines, anti psychotics, antidepressants, antianxiety drugs, beta-
blockers CP-blockers), cytostatics and antineoplastics, estrogens and hormonal 
compounds, lipid-regulators, stimulants, and X-ray contrast media. These compounds 
may be excreted unmetabolized or partially metabolized, resulting in their eventual 
passage into the environment. 
Pharmaceuticals and personal care products (PPCPs) have been detected globally 
in many natural water systems including rivers, lakes, and reservoirs (Benotti et al., 2009; 
Daughton and Ternes, 1999; Halling-Sorensen et al., 1997; Jobling et al., 1998; Jones et 
al., 2001; Kim et al., 2009; Kolpin et al., 2002; Loraine and Pettigrove, 2006; Moldovan, 
2006; Nakada et al., 2007; Snyder et al., 2001a; Snyder et al., 2001b; Yu and Chu, 2009). 
The trace amounts of pharmaceuticals that have been detected in natural waters have 
attracted more public attention and serious concern because of their potentially adverse 
effects on the aquatic environment (Jobling et al., 1998; Keith et al., 2000; Snyder et al., 
1999). Moreover, the pharmaceuticals that enter natural waters can ultimately transfer to 
our drinking water and promote unknown, but disastrous impacts on human health 
(Benotti et al., 2009; Vanderford and Snyder, 2006; Ye et al., 2007). While the risk that 
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low concentrations of pharmaceuticals pose to humans is still not being adequately 
investigated (due to their biologically-active nature), it is important to identify the 
concentrations of these compounds in natural and treated drinking waters. 
Liquid chromatography-mass spectrometry (LC-MS) (Ahrer et al., 2001; FatTe et 
al., 2001; Lindsey et al., 2001) and liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) (Asperger et al., 2001; Baronti et al., 2000; Bossi et al., 2002; Croley et al., 
2000; Hirsch et al., 1998; Jeannot et al., 2000; Lagana et al., 2000; Sacher et al., 2001; 
Ternes et al., 2001; Ternes et al., 1998; Vanderford and Snyder, 2006; Ye et al., 2007) are 
popular techniques currently being used in pharmaceutical analyses. Several published 
reviews have discussed various methods for analyzing pharmaceutical compounds that 
are found in water resources (Lopez de Aida and Barcelo, 2001; Richardson, 2008; 
Richardson, 2010; Ternes, 2001). Since most of pharmaceuticals are present in low 
concentrations in surface waters, an extraction process (e.g., solid phase extraction (SPE)) 
is often needed to concentrate target pharmaceutical compounds for analysis. 
Comprehensive studies that focus on PPCPs in Missouri's water resources and finished 
drinking water have not been conducted and reported. 
In this study, a LC-MS/MS method was developed and applied for simultaneous 
analysis of 16 pharmaceutical compounds obtained from 31 treated and untreated 
drinking water resources in the state of Missouri during both the winter and summer 
seasons. General information about the 16 pharmaceutical compounds is listed in Table 1. 
Water samples were taken from a broad range of sources, including the Mississippi River, 
Missouri River, reservoirs, lakes, unconsolidated wells, and deep wells. 
Table 1. Sixteen phannaceutical compounds and their general infonnation. 
Compounds Formula CAS# Molecular weight 
acetaminophen CgH9N02 103-90-2 1512 
caffeine CgH10N402 58-08-2 194_2 
carbamazepine C1sH12N20 298-46-4 236.3 
clo:fibric acid C10HuCl03 882-09-07 214.7 
codeine C18H21N03 76-57-3 299.4 
estradiol c18H2402 50-28-2 272.4 
estriol c18H2403 50-27-1 288.4 
estrone C1sH2202 53-16-7 270.4 
ethynylestradio 1 C 2oH240 2 57-63-6 296.4 
ibuprofen C13H1s02 15687-27-1 206.3 
iopromide C18H24l3N 308 107793-72-6 791.1 
lincomycin C18H34N206S 154-21-2 406.5 
sulfumethoxazo le CIOH11N303S 723-46-6 253.3 
triclosan C12H1Cl302 3380-34-5 289.5 
trimethoprim C14H18N403 738-70-5 290.3 





2.1. Pharmaceutical standards and reagents 
All pharmaceutical standards were purchased from Sigma-Aldrich (St. Louis, 
MO), except lincomycin (purchased from MP Biomedicals, Aurora, OH)) and iopromide 
(purchased from United States Pharmacopeia, Rockville, MD). Labeled pharmaceutical 
standards (i.e., 13C3-caffeine, 13C3-Trimethoprim, 13C2-Estrone and 13C3-Ibuprofen) were 
purchased from Cambridge Isotope Laboratories (Andover, MA). Oasis HLB extraction 
cartridges were obtained from Waters Corp. (Milford, MA), and extraction was 
performed using a vacuum manifold (Supelco, C01p., Bellefonte, P A). All solvents 
(methanol, acetonitrile, etc.) were LC-MS grade from Fisher Scientific (Fairlawn, NJ, 
USA). Formic acid (MS grade) and ammonium acetate (99.99+%) were purchased from 
Sigma-Aldrich (St. Louis, MO). Lab reagent water was purified by the Millipore Elix 3 
water purification system (Millipore, Bierica, MA). 
2.2. Sample collection and preservation 
Sample collection, preservation, and storage were accomplished by following the 
US EPA Method Guideline (US EPA method 1694, 2007). Sample bottles used to collect 
water samples were new 500-mL amber glass bottles with Teflon® liner screw caps. 
Prior to use, bottles were pre-cleaned with Mill-Q water, methanol, acetone, and Mill-Q 
water, and then baked at 105°C for at least 2 hr. Forty mg of sodium thiosulfate were 
added to each bottle to reduce any residual chlorine that had been added as a disinfectant. 
To collect treated tap water samples, the water was allowed to flow from the tap without 
an aerator for about 5 min, prior to completely filling the sample bottle, with no 
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headspace. To collect raw (untreated) water, a large pre-cleaned wide-mouth bottle or 
beaker was used, and then the water was carefully transfened from the original container 
to a sample bottle that was completely filled with no headspace remaining. Sodium 
thiosulfate should not be flushed out during the collection of either treated or untreated 
water. The bottles were then sealed and agitated by hand for about one minute. Two 
bottles of untreated source water sample and two bottles of treated water samples were 
collected from each water treatment facility. The samples were kept on ice and shipped 
overnight to the laboratory for analysis. Upon arrival, the samples were immediately 
preserved by adjusting the pH to 5 with sulfuric acid, and then stored at 4°C until 
extraction (normally, within 2 days after an·ival). 
2.3. Solid phase extraction 
Solid phase extraction was performed by following US EPA method 1694 (US 
EPA, 2007), with some modification and validation. Water samples were first filtered 
using 0.45-!.tm nylon membrane filters (Whatman, England), and then acidified to pH 
2.0±0.2 using HCI. One hundred twenty-five mg ofN84EDTA·2H20 were then added for 
each 250 mL of water sample. 50 !.!L internal standard mixture (concentration 1 !.lg/mL ) 
was spiked in the water. Solid phase extraction was conducted using Oasis HLB 6cc (200 
mg) cartridges conditioned with 6 ml of methanol, 2 ml of Milli-Q water, 2 ml of pH 2.0 
Milli-Q water, and 6 ml of Milli-Q water. Next, 250 ml of each water sample was 
extracted, at a flow rate of 1-2 drops per second. After extraction of the sample, each 
cartridge was washed with Sml Milli-Q water to remove any EDT A residue. The 
cartridges were dried under vacuum for 5 minutes. Analytes were eluted from the 
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cartridge by using 5ml of methanol and then 3 ml of an acetone-methanol (1: 1) mixture 
were placed into a clean test tube. The combined eluent was evaporated to 100 J.lL by 
using a Turbovap LV evaporator at 50±5°C. Nine hundred J.lL of 20% acetonitrile in MQ 
water with 0.1% formic acid was then added to each sample tube and the contents were 
vo1tex mixed. Finally, the samples were transfe1Ted to 2-mL amber glass sample vials, 
and stored in a refrigerator until LC/MS/MS analysis. 
2.4. LC-MS/MS analysis 
A 4000Q TRAP mass spectrometer (AB SCIEX, Concord, ON, CA), equipped 
with an Agilent 1100 series HPLC system (Agilent Technologies, Inc.,Santa Clara, CA, 
USA), was used for all analyses. A sample volume of 10 J.ll was injected. The HPLC 
column was a Supelco C-18 column (150x2.1 mm, 5-J.lm pmticle size, Sigma-Aldrich, St. 
Louis, MO). Different mobile phase additives were used for positive electrospray 
ionization (ESI+) and negative electrospray ionization (ESI-) mode analyses. The mobile 
phase for ESI+ compounds consisted of 0.1% formic acid (v/v) in water (A) and 0.1% 
formic acid (v/v) in acetonitrile (B). Elution flow rate was 0.25 mL!min. The mobile 
phase for ESI- mode compounds consisted of 5 mM of ammonium acetate in water (C) 
and 100% acetonitrile (D). Elution flow rate was 0.25 mL!min. For both ESI+ and EST-
mode compounds, the gradient began with 5% solvent B or D for 1.5 min, ramping to 
75% B or D at 2.5 min, 15% B or D at 13.5 min, and 100% B or D at 15 min, where it 
was held for 1.5 min. Mass spectrometry utilized both ESI+ and ESI- modes in multiple 
reaction monitoring (MRM). Mass spectrometers, including mass calibration, polarity of 
each compound, compound-dependent parameters, and source-dependent parameters 
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were all optimized for each compound. After optimization, the ion transition with the 
most intense signal was selected as the quantification ion pair of the conesponding 
compound, while the ion transition with the second highest signal was selected as the 
confirmation ion pair of the corresponding compound. In positive mode, the ion source 
temperature was set at 650°C with an ion spray voltage of 5000 V. The nebulizer gas, auxiliary 
gas, and cmtain gas were 50, 65, and 25 psi, respectively. In negative mode, the ion source 
temperature was set at 550°C with an ion spray voltage of -4500 V. The nebulizer gas, auxiliaty 
gas, and cmtain gas were 50, 60, and 30 psi, respectively. 
2.5. Quality control 
During the method development, the liner range of calibration for each compound, 
method detection limit, reagent blank, reproducibility, spike recoveries of each 
compound in reagent water and in drinking water matrices were all performed. During 
the analysis of water samples, at least one blank, one duplicate, and one spike were 
proceeded with sample preparation and LC-MS detection for each batch (there were 
generally 8 water treatment facilities in each batch). The choices of these sample matrices 
represented river water, lake water, well water, and reservoir water. 
3. RESULTS AND DISCUSSION 
3.1. HPLC separation and mass spectrometry detection 
Each sample was injected for both ESI+ and ESI- analyses. Ten of the 16 
compounds were detected with ESI+ and six of the compounds were detected with the 
ESI- mode. The retention times and compound dependent mass spectrometry parameters 
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of the target pharmaceuticals are listed in Table 2. Most compounds were well separated 
chromatographically. Several analytes, that were not well separated chromatographically, 
were monitored at different MRM ion pairs. All pharmaceuticals were optimized 
individually for maximum sensitivity. The dwell time for each compound was also 
optimized, depending on their peak width thereby allowing the peaks to be integrated 
accurately and with high sensitivity. 
3.2. Method detection limit and possible interference in water sample matrix 
The method detection limit (MDL) for each compound was determined by 
following U.S. EPA method (EPA-821-R-03-005), spiking 9 replicates of 2-5 times 
concentration of the estimated instrumental detection limits (IDL) (before 250x 
concentrated by SPE) (The IDL of each PPCP compound was determined based on the 
PPCP concentration at signal-to-noise ratio of 3-5). The spiked PPCP standards were 
proceeded by SPE and then analyzed by LC-MS/MS. The MDL of each compound was 
calculated by multiplying the standard deviation(s) of the replicate analyses by the 
Student's T value for eight degrees of freedom at the 99 percent confident level. The 
MDL in both reagent water and tap drinking water were determined separately. A sample 
matrix was analyzed first to assess the concentrations of the target pharmaceutical 
compounds. For the tap water matrix, since some target analytes were found to be 
present in the water, each pharmaceutical standard was spiked individually to make the 
concentrations of pharmaceuticals fall to 2-5 times the estimated IDL and proceeded to 
determine MDL. The method detection limits of studied pharmaceuticals are listed in 
Table 3. 
Table 2. LC-MS/MS e::q>erimental conditions of the sixteenphannaceutical compotmds. 
Compounds Retention ESI 
mode 
Precursor Product Dedustering Collision 
time (min) mode ion ion potential (V) energy ~ 
acetaminophen 5.7 positive 151.8 110 66 25 
caffeine 8.2 positive 194.9 138 51 31 
carbamazepine 11.7 positive 236.9 194 71 31 
clofibric acid 8.1 negative 212.9 126.8 -40 -24 
codeine 7.9 positive 300 215 81 37 
estradiol 13.1 positive 255 159 76 29 
estriol 8.8 negative 286.7 171.1 - 100 -50 
estrone 12 negative 268.9 144.8 - 110 -54 
ethynylestradiol 13.8 positive 279 133.2 61 27 
ibuprofen 9.5 negative 204 .9 159 -55 -10 
iopromide 3.5 negative 789.9 126.7 -85 -48 
lincomycin 8 positive 407.1 126.2 76 39 
sulfumet:OOxazole 10.2 positive 253.9 156 61 25 
trick> san 15.8 negative 286.7 35 -50 -110 
trimet:OOprim 8.3 positive 291 230.2 81 35 








































Table 3. Method detection limits (MDL), spike recovery and relative standard deviation (RSD) of studied phannaceuticals in reagent 
water (Deionized (DI)) water and tap water mat:ri~ (n=9). 
:\IDL (ng/L) Higb-le,·el spike Low-Je,·el spike 
DI water Tap Water Dl \\'liter I~ Water Componnd 
DI Tap Spike Recore~· RSD Spike Recorery· RSD Spike Recorery RSD Spike Recovel)· RSD 
Water Water (ng/L) (%) (%) (ng/L) (%) (%) (ngiL) (%) (%) (ng/L) (%) (%) 
acetamincphen 2.7 1.4 200 95.8 10.4 200 IOO 6.9 IO 106 8.8 10 73.9 6.4 
caffeine 0.8 l.l 400 109 9.1 400 ll5 8.5 2 46.4 29 2 50.7 37.4 
carOOma.zepae 0.5 01 200 104 4.9 200 I2I 'i ~ .. ) I I25 13 I 125 5.9 
clofibric acid 1.3 0.6 400 122 12.9 400 157 7.4 I 72.6 28.1 I 56.7 37.5 
codeine 1.0 1.5 400 104 2.6 400 122 4.5 5 I45 4.7 5 I 50 6.7 
estradiol 0.8 I1 400 95.6 5 400 106 4.4 5 I02 5.3 5 97.9 8.7 
estriol 4.3 5.2 200 I28 4.9 200 115 2.4 20 I20 6.2 20 121 7.4 
estrooe 1.4 1.0 200 116 2.6 200 109 1.9 2 891 26 2 123 13.9 
ethynylestradid 0.1 0.5 200 92.3 6.2 200 102 2.8 1 108 4.4 1 75.8 22 
ibuprofen 1.0 1.6 400 119 1.9 400 110 2.2 20 106 3.5 20 85.9 ' ' :u 
ioprooride 3.5 9.9 200 98.1 8.8 200 90.6 7.8 20 136 4.4 20 153 111 
lincomycin 0.1 0.1 200 103 9.9 200 97.5 5.6 1 12.6 32.8 1 7.1 55.2 
sulfamethoxazole 0.4 0.3 400 90 11.5 400 102 4.7 1 90.5 14.8 1 92.7 9.3 
tricbsan 1.0 1.2 400 32 14.1 400 33.6 15.7 10 39.3 8.7 10 29.8 131 
trimethoprim 0.3 0.4 400 123 11.3 400 125 4.9 1 91.2 121 1 91.2 14 




3.3. Spike recovery 
Spike recoveries in both reagent water and tap water were determined separately. 
For each type of water, two concentrations (low and high) and nine replicates of each 
concentration were performed discretely. High and low concentrations were selected to 
cover the most likely range of pharmaceutical concentrations that would be expected to 
be observed in actual treated and untreated water samples. Recoveries of all compounds 
were determined by adding an appropriate amount of standard solutions of the target 
pharmaceutical compounds to 250 ml of reagent and real water samples. The recovery 
study consisted of four experiments. For each experiment involved, known 
concentrations of target pharmaceutical compounds were prepared in nine replicate water 
samples (250 ml water each). The samples were proceeded by SPE and then analyzed by 
LC-MS/MS. The relative percent recoveries and relative standard deviations were 
calculated, and are reported in Table 3. 
Recoveries of most of the high concentration pharmaceutical compounds (200-
400 ng/L) in reagent and tap water ranged between 90-130%. The recoveries of tylosin 
and triclosan, however, were relatively low in both water matrices, while the recovery of 
clofibric acid was high in the tap water matrix. The results of recovery studies, in most 
cases, showed excellent reproducibility with the percent relative standard deviation being 
less than 10%. Most of the compounds at the spiked concentrations behaved similarly 
between the two different water matrices. 
Recoveries of the pharmaceutical compounds at low concentration spikes 
(ranging 1.0 -20 ng/L, which was near the MDL for most of the compounds) ranged from 
50-150% for most of the compounds. Majority of the compounds also showed good 
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reproducibility, with the percent relative standard deviation being less than 15%. For 
most of the studied compounds, the low concentration recoveries did not show significant 
differences between the two water matrices. However, some compounds, such as 
Lincomycin, triclosan, and tylosin, had low recovery in both reagent water and tap water 
matrices. Acetaminophen and ethynylestradiol had relatively lower recoveries in tap 
water. Lincomycin also had a lower recovery and much higher percent relative standard 
deviation in the tap water matrix than reagent water matrix. This phenomenon was also 
reported in US EPA method 1694. Ideally, an isotope-labeled internal standard should be 
used for each of the studied compounds. However, only four labeled internal standards 
were used in this study due to the limited budget. Different isotope-labeled internal 
standards used in this study may also have contributed to the poor recoveries of 
pharmaceuticals. 
During pharmaceutical occurrence study in Missouri water, spike recoveries were 
also tested with each batch of samples and each major water type (river, lake, and well). 
The recoveries were similar with or better than the initial recovery studies as shown 
above. 
3.4. Occurrence of pharmaceuticals in Missoul"i drinking water systems 
Treated and untreated waters were sampled from 31 different water treatment 
facilities across Missouri in both the cold (winter) and warm (summer) seasons. These 
water treatment facilities used varied source waters, including rivers, reservoirs, lakes, 
unconsolidated wells, groundwater, and deep wells. The water samples from these water 
treatment plants represent the most common tap drinking water in Missouri. The water 
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treatment plants on the Missouri and Mississippi Rivers utilize conventional treatment 
(i.e., pre-sedimentation, rapid mix, flocculation, sedimentation, filtration, and disinfection) 
including two-stage lime softening. Specifically, the treatment plants utilize ferric 
chloride or sulfate coagulants, chlorine as the primary disinfection, and chloramine as the 
residual disinfectant. Periodic powdered activated carbon addition is also used. All of the 
water facilities that participated in this study used chlorine and chloramines as water 
disinfectants. Both untreated and treated water samples were collected from each water 
treatment facility at same time to evaluate the effects of the water treatment process on 
the studied pharmaceuticals. 
In the winter season, 11 pharmaceutical compounds (Table 4) were detected in at 
least one of the untreated source waters: Caffeine was found in all of the untreated and 
treated water samples, with concentration ranges of 2.5-225 ng/L, and were present at 
higher levels than most of the other pharmaceuticals monitored in this study. Caffeine 
concentrations were higher in river water than in most of the other types of water. In most 
cases, lower concentrations were detected in treated waters (free chlorine or chloramines) 
than in untreated waters, indicating some removal of this compound by the water 
treatment process. Carbamazepine was found in 11 of the 31 water treatment facilities 
studied, in both treated and untreated waters at concentrations up to 8.7 ng/L. The 
concentrations were also lower, however, in treated water than in untreated water. This 
compound was found in all river water samples. Sulfamethoxazole was present at a 
detectable level in 11 out of the 31 water treatment facilities, primarily in untreated river 
waters, with a maximum concentration of 38.1 ng/L. This indicated that the water 
treatment effectively removed most of this compound. Ibuprofen was also found in both 
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untreated and treated waters in 7 of the 31 water treatment facilities; 6 sources were from 
rivers with a highest concentration of 77.2 ng/L. The concentrations of this compound 
were found to be about the same before and after water treatment, indicating that the 
water treatment procedure used was not effective in removing this pharmaceutical. The 
concentrations of the rest of the target compounds were all below method detection limits. 
These results indicate that the concentrations of detected pharmaceutical compounds 
were water source dependent and were usually higher in river water and other types of 
surface water samples than concentrations found in the underground water samples. A 
probable reason could be that the rivers receive all of the effluent, and other types of 
surface water (such as lakes and reservoirs) receive water flows from surrounding areas. 
In the summer season, fewer compounds were detected in water facilities (Table 5). 
These compounds were tylosin, lincomycin, thrimethoprim, sulfamethoxazole, 
acetaminophen, caffeine, carbamazepine, and triclosan. The relative concentrations of 
the detected compounds in different types of water sources in water samples during the 
summer shared a trend similar to that of water samples collected during the winter season. 
The difference between the two seasonal water samples was the level of concentration of 
the detected compounds. Concentrations of pharmaceutical compounds were lower in the 
summer than in the winter. One of the possible reasons for this difference might be due to 
more degradation of these pharmaceuticals in a warmer environment. The other reason 
may be attributed to the normally heavier rainfall during the summer season in Missouri 
vs. that in the winter season, since increased rain reduces the concentrations of the target 
compounds. In addition, variation of the concentration over time might have some 
contributions because grab-sampling method was used. Caffeine is a commonly used 
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tracer pharmaceutical due to its relatively higher concentrations, and due to its relatively 
constant daily use. Based on stream flow and concentration data, the caffeine mass flow 
rate in the Missouri River was 88.8, 141.6, 97.6, and 131.1 mg/s, respectively, for 
January, April, May, and June, 2009. The mean and relative standard deviation were 115 
mg/s and 22%. Similarly, the caffeine mass flow rate in the Mississippi River was 281, 
238, 284, and 183 mg/s, respectively, for January, April, May and June, 2009. The mean 
and relative standard deviation were 247 mg/s and 19%. These relatively small relative 
standard deviations in mass flow rate for caffeine are an indication of the great 
impot1ance of dilution effects. Similarly, the effect of dilution by increased flow in the 
summer vs that in the winter, creates a relatively constant input of a chemical, as seen by 
the relatively strong inverse correlations between river flow rates and concentrations. For 
example, for sulfamethoxazole and caffeine in the Missouri River, the inverse conelation 
coefficients were -0.89 and -0.98. For sulfamethoxazole and caffeine in the Mississippi 
River, the inverse correlation coefficients were -0.77 and -0.89. Thus, the effects of 
seasonal dilution are clearly, at least pattially, responsible for the trends observed. 
By following guidance from Missouri Department of Natural Resources, three 
types of water matrixes (Mississippi River water, reservoir water and Missouri River 
water were sampled monthly from winter to summer for more detailed assessments of 
changes in the trend of applicable pharmaceutical compounds. Assessment results 
showed that eight pharmaceutical compounds were detected in Mississippi River and 
Missouri River water samples (lincomycin, trimethoprim, sulfamethoxazole, 
acetaminophen, caffeine, carbamazepine, triclosan, and ibuprofen), with the caffeine 
level being the highest. Pharmaceutical compound levels found in both Mississippi River 
Table 4. Phannaceutical concentration of real water samples in winter season. 
ID 













Free chlorine Untreated <MDL 4.2 
Treated <MDL <MDL 
Cbloramines Untreated <MDL <MDL 
Treated <MDL <MDL 
Cbloramines Untreated <MDL 1.8 
Treated <MDL <MDL 
Cbloramines Untreated <MDL 1.1 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
6 Deep rock wells Cbloramines Untreated <MDL <MDL 
Treated <MDL <MDL 
7 Deeprockwells Freechlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
8 Reservoirs Freecblorine Untreated <M DL <MDL 
Treated <MDL <MDL 
9 Reservoir Cbloramines Untreated <MDL 2.5 
Treated <MDL <MDL 
10 MO River Cbloramines Untreated <MDL 2.9 
Treated <MDL <MDL 
Concentration (n:JL) 
Trimeth~ Sul!.ameth- Acrtamin- Cal-

















































































ND =No Data MDL= Mc:t1toclDctcction Limit 












<MDL <MDL 16.6 <MDL 
<MDL <MDL 8.8 
<MDL <~DL 37.5 
<MDL 
22.4 
<MDL <~DL 26.6 <MDL 
<MDL 2.1 27.1 <MDL 
<MDL <~DL 23.4 <MDL 
<MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <~DL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
1.9 <MDL 9.8 
<MDL <MDL 2.8 
<MDL <MDL 
<MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL 3.4 <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
1.0 <MDL <MDL 2.4 <MDL 
<MDL <MDL <~DL 2.0 <MDL 
8.1 3.7 <MDL 772 <MDL 
6.8 <MDL <MDL 7.2.8 <MDL 
N 
1.0 
Table 4. (continued) 
ID 
# Water source 




IS Deep Well 
16 Deep Well 
17 Deep Well 





Sample T~·lo- linc:o- Trimetho- Sulfameth- Acetamin- Caf- Carbama- Code- Triclo- lbup- Iopr-
Treatment type sin m~·c:in prim oxazole ophen feine zepine ine san rofen omide 
Freec:hlorine Untreated <MDL 2.8 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Chloramines 
Chloramines 
Treated <MDL <MDL 
Untreated <MDL <MDL 
Treated <MDL <MDL 
Untreated <MDL <MDL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
Freechlorine Untreated <MDL ~\l:DL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Treated <MDL <.t\fDL 
Free chlorine Untreated <MDL ~\fDL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Treated ND N"D 
Free chlorine Untreated ND KD 


















































































8.1 3.0 <MDL 13.6 <MDL 
3.2 <MDL <MDL 10.4 <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <~DL <MDL <MDL <MDL 
<~DL <MDL <MDL <MDL <~DL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 













<MDL <~DL <MDL <MDL <MDL 
w 
0 
Table 4. (continued) 
ID 


























Treatment (Hit sin mycin 
Free chlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL 1.1 
Treated <MDL <MDL 
Free chlorine Untreated 4.3 <MDL 
Treated <MDL <MDL 
Chloramines Untreated <MDL 7.7 
Treated <MDL <MDL 
Freechlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL 1.1 
Treated <MDL <MDL 
Chloramines Untreated <MDL <MDL 
Treated <MDL <MDL 
Free chlorine Untreated <MDL <MDL 
Treated <MDL <MDL 
Chloramines Untreated <MDL <MDL 
Treated <MDL <MDL 
Coacentratioo (n:IL) 
Trimetho- Sulfameth- Acetamin- Car-

























































































·No =No Data MDL =Method Detection Limit 
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<MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
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<MDL <MDL <MDL <MDL <MDL 
4.S <MDL <MDL <MDL <MDL 
3.5 <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <MDL <MDL 
<MDL <MDL <MDL <M DL <MDL 
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1.4 
<MDL <MDL 4.4 
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<MDL 
<MDL 
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Table 5. Phannaceutical concentJ:ation of real water samples in swmner season. 
C.cmtatila(~ 
Slllllflle TJI-- lac. ~~ SlllfultA- .la:4wrio- c.J.. ea...-
1)1 W:der:S~~~Ut:e T~t .. sia .,.... ..-
-· 
.til ra- zepiae 
1 MSRm Fm:dabDc: UDiralal -<MDL 2.6 <MDL (.2 -<MDL 15.6 5..7 
Tmtal -<MDL <MDL <MDL <MDL <MDL 9.5 LD 
2 MSRm UDiralal <MDL 4.6 <MDL lLO -<MDL 134..8 8.6 
Tmtal <MDL 2.0 <MllL <MDL -<MDL 22..8 s..o 
3 MORivcr Chb•lil•s UDiralal -<MDL 1.9 <MDL 4.6 -<MDL 1:1.6 u 
Tmtal -<MDL <MDL <MllL 4J) <MDL 124 1.5 
4 AhiiiGW ~ I UDiralal -<MDL 13 <MDL 4.8 <MDL 324 83 
Tn:lltal -<MDL <MDL <MDL 13 <MDL &.8 1.4 
s Ahiii.GW Fm:d!bime UDiralal -<MDL <MDL <MllL 3.9 <MDL 72 -<MDL 
Tmtal -<MDL <MDL <MDL <MDL <MDL 72 <MDL 
6 Dap lOCi. wells CJ:obwWn UDiralal -<MDL <MDL <MDL <MDL <MDL 18.4 1.3 
T1CIIIal <MDL <MDL <MDL <MDL <MDL 20.9 <MDL 
7 Dap lOCi. well Fa: d!biDe UDiralal <MDL <MDL <MDL <MDL <MDL 14.1 <MDL 
T1CIIIal -<MDL <MDL <MDL <MDL <MDL 6.1 <MDL 
8 Rcavoim F111:dlbiac UDiralal <MDL 3.D <MDL <MDL <MDL S6.0 -<MDL 
T1CIIIal <MDL <MDL <MllL <MDL <MDL 17.8 <MDL 
9 ~-- UDiralal -<MDL 13 <MDL <MDL <MDL 6.6 <MDL 
T1CIIIal -<MDL <MDL <MDL <MDL <MDL 1.2 -<MDL 
10 MORivcr UDiralal -<MDL <MDL <MDL au 9.4 46.0 7.3 
T1CIIIal <MDL <MDL <MllL 1.6 6.2 35..6 s..o 




































































Table 5. (continued) 
s-.~e T,S.. lac. r.-...s~ 
1)1 W.krs.mE Tn:at.mt ~ .. .,a. ..-
-· 11 MS:Rift:t FtllC dlbimc l.Tutn::llal 4tmL 3.9 ~ 4.0 
Ttatal 4tmL <MDL ~ <MDL 
u :r..Kt: FtllCdllarimc l.Tutn::llal 4tmL -<MDL <MDL <MDL 
TJatal -MDL -<MDL <MDL <MDL 
13 :r..Kt: U!m:llal -MDL <MDL <MDL 1.9 
TJatal -MDL <MDL <MDL <MDL 
14 :r..Kt: l.Tutn::llal -MDL <MDL <MDL <MDL 
TJatal -MDL -<MDL ~ <MDL 
IS DapWc:B Fm:dllarimc l.Tutn::llal -MDL -<MDL ~ <MDL 
TJatal -MDL <MDL ~ <MDL 
16 DapWcD Fm:dllarimc 'Untratal <MDL <MDL -<MDL <MDL 
TJatal -MDL <MDL <MDL <MDL 
17 DapWcl Fm:dlbimc 'Untratal -MDL <MDL <MDL <MDL 
TJatal <MDL <MDL <MDL <MDL 
18 Dap'Wdl Fm: dlbimc 'Untratal <MDL <MDL -<MDL <MDL 
TJatal -MDL <MDL <MDL <MDL 
19 :r..Kt: FKICdllarimc U!m:llal -MDL <MDL <MDL L1 
TJatal <MDL <MDL <MDL <MDL 
7D lJuc:uauiddal F~~r:dllarimc U!m:llal 3.9 7.0 5.1 3.2 
Wdls TJatal <MDL u (.7 LS 
ND = Noi>G MDL= Mcthodl>dcdDlliDt 
O.CI!IIb-(~ 
.a. .. _.__ ~ c...-
... m Ia- xqja.e 
46..0 25.3 u 
9.5 11..6 u 
328 S9.6 <MDL 
9.4 16.4 4tO)L 
-MDL 6.D <MDL 
-MDL 33 -MDL 
-MDL 75.6 -MDL 
-MDL 14.6 -MDL 
4tmL L7 <MDL 
-MDL u -MDL 
4tmL 1.6 <MDL 
-MDL u <MDL 
-MDL 14.9 4tO)L 
4tmL 6.S 4tO)L 
-MDL 14.5 -<MDL 
4tmL 6.3 <MDL 
4tmL 16.4 1..6 
4tmL 14.9 <MDL 
4tmL lll 9.6 





































































Table 5. (continued) 



























type sill ..,.. 
UD~ratal <;MDL <MDL 
T!Sal <;MDL <MDL 
UDirellal <;MDL <MDL 
Tmted <;MDL <MDL 
UD~ratal <;MDL <MDL 
Tmtal <MDL <MDL 
UD~rate:l <MDL <MDL 
Tmtal <MDL <MDL 





Tmted <MDL <MDL 
UDirelled <MDL <MDL 
T!Sal <MDL <MDL 
UDirelle:l <MDL <MDL 
Tmted <MDL <MDL 
UDirelle:l <MDL <MDL 
Tmted <MDL <MDL 
UDirelle:l <MDL <MDL 
Tmted <MDL <MDL 
UDirelle:l <MDL <MDL 
C..cab-.<-oQ 
Tm.ea.- Slllflaea.. ~ Cal- C..... 
pm -• l(llla ra-e •q*e 
<MDL <MDL <MDL S.Z <;MDL 
<MDL <MDL <MDL LS <;MDL 
<MDL <MDL ~L 152..0 40>L 
<MDL <MDL ~L 1..2 <;MDL 
<MDL <MDL ~L llU 40>L 
<MDL <MDL <MDL 9..6 13 
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water and Missouri River water were similar. In the reservoir water samples, however, 
only four compounds were detected (lincomycin, acetaminophen, caffeine, and triclosan) 
and their concentrations were much lower than those detected in Mississippi River and 
Missouri River water samples. The monthly monitoring also showed a decrease in the 
concentrations of detectable pharmaceutical compounds from February to June. Specific 
concentrations of all target pharmaceutical compounds in treated and untreated waters 
samples in this seasonal study are reported in Table 6. 
One of the largest studies of pharmaceutical occurrence in untreated drinking 
water sources from the U.S. Geological Survey (Focazio et. a!., 2008) concluded that the 
concentrations of most detected compounds were typically in the sub-iJg/L range. This 
matched our results. Our study also indicated that the highest concentrations of the 
detected pharmaceuticals in Missouri were lower than the maximum concentrations in 
Focazio's repm1. In our study, caffeine was much more frequently detected than in their 
national survey. However, the MDL in national survey (14 ng/L) was several times 
higher than the MDL in this study (1.1 ng/L). The maximum concentrations of caffeine in 
our study were 0.22 11g/L whereas the national survey reported 0.27 iJg/L. 
3.5. The removal efficiency by water treatment facilities 
Since untreated and treated water samples were collected at the same time from 
each water treatment facility, the pharmaceutical concentration difference should 
represent the removal efficiency of water treatment. Free chlorine and chloramines were 
used as disinfectants in these selected water treatment p !ants. A general decrease in 
concentrations of target pharmaceuticals in finished drinking water was observed in 
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occurrence study. Both treatments showed comparable removal efficiencies of 
acetaminophen. The main site of transformation of acetamination during chlorine 
oxidation was reported as the phenol group (Pinkston and Sedlak, 2004). On the other 
hand, results indicated that the removal of carbamazepine was not effective by 
chlorination or chloramination treatment. Most water treatment plants failed to remove 
this compound to below detection limit. This result matched previous studies by Benotti 
et al and Stackelberg et al.. (Benotti et al., 2009; Stackelberg et al. 2007). However, it has 
reported that carbamazepine can be efficiently removed by chlorination at low pH 
(Westerhoff et al. 2005). The removal efficiency of Caffeine was also found low by 
chlorination or chloramination treatment in the occunence study. This was generally in 
agreement with observations by Syder et al. It was found that the removal efficiencies of 
caffeine by chlorination or chloramination were below 20% after 24 hrs at pH 7.9-8.5 
(Syder et al. 2007). 
There was also some difference on removal efficiency between chlorination and 
chloramination treatments. Occurrence results indicated that 8 of 9 water treatment plants 
removed sulfamethoxazole to below detection limit with chlorination treatment. Only 4 
of 10 water treatment plants removed sulfamethoxazole to below detection limit with 
chloramination treatment. Similar results were also founded by Stackelberg et al. 
(Stackelberg et al. 2007), sulfamethoxazole in source water can be effectively removed 
after chlorination treatment. The less effective oxidation efficiency of sulfamethoxazole 
and tylosin was also reported by Chamberlain et al. (Chamberlain and Adams, 2006). 
Other studies repotted that the sulfamethoxazole aniline-nitrogen was directly attacked by 
chlorine (Dodd and Huang, 2004). 
Table 6. Seasonal monitoring ofPPCPs fi:om Febmru.y to J1.me 2009. 
as.. a Water -.a> Tntat.eat 
MO ltiver F n:oe chJariDe 
Feb R.c::savoir 
MSJtiver CbJoiaoiiMs 
MO River CbJoiaoiiMs 
April R.c::savoir Fn:oe ddaDDe 
MSJtiver CbJoiaoiiMs 
MOJtiver F n:oe chJariDe 
!by R.c::savoir Fn:oe chJariDe 
MSJtiver CbJoiaoiiMs 
MOJtiver CbJoiaoiiMs 
Juuc R.c::savoir Fmc dllaDDe 
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The distribution of these compounds was water source dependent. River water 
and surface water samples had higher concentrations of studied pharmaceutical 
compounds, although concentrations of pharmaceutical compounds in well water were 
much lower. This is understandable since well water is purified by underground materials, 
such as sand and dirt filtration. Results also showed that most of the investigated 
phatmaceutical compounds were not detectable after water treatment. However, the 
removal efficiency by water treatment plants was compound dependent. Some 
pharmaceutical compounds, such as lincomycin, trimethoprim, and sulfamethoxazole, 
were relatively easier to remove than other compounds, such as ibuprofen, 
carbamazepine, and caffeine. Even though some pharmaceuticals were still detectable 
after treatment, the concentrations were much lower than those in the untreated water, 
which implied that most phatmaceutical compounds can be effectively removed during 
water treatment. 
4. CONCLUSIONS 
A comprehensive method has been developed and validated for quantitative 
analysis of 16 pharmaceutical compounds in two different water matrices, using liquid 
chromatography coupled with tandem mass spectrometry. Most selected compounds 
investigated by this method showed good recovery and reproducibility in reagent water 
and tap water. The results of the occurrence study indicated that the levels of selected 
compounds in different types of water resources across Missouri were below 80 ng/L for 
all of the pharmaceuticals, except caffeine, which had the highest concentration, while 
levels of other compounds were very low. Most of them were below method detection 
limits. The levels of the studied pharmaceutical compounds were also water source 
39 
dependent. Studied pharmaceutical compound concentrations were higher in surface 
water than those in well water. Occurrence data also showed that the levels of the most 
pharmaceutical compounds in summer water samples were lower than those found in the 
winter water samples. The treatment processes in water facilities across Missouri were 
found to be effective for removing most pharmaceutical compounds. 
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2. Investigation of Oxidative and PAC Removal of Selected 
Pharmaceuticals in Various Oxidation Systems by Using 
Liquid Chromatography Tandem Mass Spectrometry 
ABSTRACT 
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The presence of pharmaceuticals and personal care products (PPCPs) in natural 
water resources and drinking water supplies has raised public concern because of their 
potential adverse ecological effects on aquatic organism or even on human health. The 
study of pharmaceutical elimination is crucial in providing information for the 
disinfection strategy in water treatment facilities. This study investigated both the 
treatability and removal of eight pharmaceuticals (caffeine, acetaminophen, 
carbamazepine, sulfamethoxazole, trimethoprim, erythromycin, lincomycin, and codeine) 
as a function of treatment approaches, types of disinfections (free chlorine, ozone, 
monochloramine, and petmanganate ), and pHs, by using liquid chromatography- tandem 
mass spectrometry (LC-MS/MS). Both deionized (DI) water and natural water were 
spiked with 5 to 20 ).I giL of pharmaceuticals and dosed by commonly used oxidants at a 
typical concentration followed by analysis using LC-MS/MS. It was found that the 
degradation levels of the pharmaceutical compounds varied significantly in different 
oxidation processes. Chlorination at 1 mg/L was highly effective in removal of some 
phatmaceuticals. Monochloramine at a dose of 3 mg/L was mostly ineffective to all the 
pharmaceuticals tested. The pH conditions also played an important role in PPCP 
removal, and its effect was conditional based on the oxidation systems and 
pharmaceuticals involved. Finally, powered active carbon (PAC) was also evaluated for 
its effectiveness in the removal of the pharmaceuticals in drinking water treatment. 
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1. INTRODUCTION 
Pharmaceuticals and personal care products (PPCPs) have been detected in many 
natural water systems as well as drinking water supplies (Ahrer, Scherwenk, and 
Buchberger 2001; Benotti et al. 2009; Hirsch, Ternes, and Haberer 1998; Jones, 
Voulvoulis, and Lester 2001; Kolpin et al. 2002; Lindsey, Meyer, and Thurman 2001; 
Sacher et al. 2001; Ternes, Bonerz, and Schmidt 2001). The potential occurrence of 
pharmaceuticals in drinking water supplies raises public concerns because available 
treatment data and the information about combined and synergistic effects of different 
types of pharmaceuticals are limited. It is already known that some pharmaceuticals can 
cause adverse biological impacts on aquatic and terrestrial organisms at ve1y low 
concentrations (Fent, Weston, and Caminada 2006; Jjemba 2006). Due to the possible 
existence of pharmaceuticals and their metabolites in water supplies and the food chain, 
some risk assessments have been performed to indicate the possible impacts of 
pharmaceuticals on ecosystems (Bound and Voulvoulis 2006; Stuer-Lauridsen et a!. 
2000). Even though current toxicity data show no acute effects of pharmaceuticals in 
surface water on aquatic organisms (Flippin, Huggett, and Foran 2007; Heruy and Black 
2008; Henry et al. 2004; Hong et al. 2007; Schreurs et al. 2004), chronic effects and 
bacterial resistance to antibiotic pharmaceuticals may exist. As a result, attention should 
be given to the long term concerns regarding the accumulation and spread of non-
degraded pharmaceuticals in the environment. 
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Reliable information for pharmaceutical elimination from surface water can be 
critical to water treatment plant operations because surface water is widely used as a 
source for municipal water systems. To minimize the risk of potential chronic harmful 
effects, drinking water should be free of pharmaceuticals. Some recent studies have 
already reported the oxidation of pharmaceuticals by chlorine and ozone (Stackelberg et 
a!. 2007; Westerhoff et a!. 2005). Ozone is an effective oxidant for the effective 
degradation of pharmaceuticals and has been well studied (Broseus et a!. 2009; Hua, 
Bennett, and Letcher 2006; Vieno et a!. 2007). In some studies, hydrogen peroxide was 
combined with ozone to create an advanced oxidation method for pharmaceutical 
decomposition (Huber et a!. 2003; Zwiener and Frimmel 2000). There are also some 
studies reported the oxidation of pharmaceuticals by permanganate and chloramines 
(Chamberlain and Adams 2006; Waldemer and Tratnyek 2006), however, they did not 
cover all the compounds we found in Missouri natural and drinking water in our 
occurrence study. 
In our recent occurrence study on pharmaceuticals in Missouri water resources , 
some pharmaceuticals were detected in both untreated source water and treated drinking 
water, including caffeine, acetaminophen, carbamazepine, sulfamethoxazole, 
trimethoprim, and ibuprofen (Wang eta!. 2010). The aim of this presented research was 
to investigate the treatability of these compounds by using liquid cluomatography -
tandem mass spectrometry (LC-MS/MS). Eight pharmaceuticals were chosen to evaluate 
oxidation effectiveness of the following commonly used oxidants in water treatment 
plants: free chlorine (HOCl/OCl), monochloramine, ozone (03), and permanganate 
(Mn04"). Powered active carbon (PAC) was also evaluated for its effectiveness in the 
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removal of the pharmaceuticals. The PAC removal efficiency in DI water was compound 
dependent. The major task of this study was to investigate the concentration x time (CT) 
values for the oxidation reactions of selected pharmaceuticals with the four chosen 
oxidants in deionized (DI) water. The pH effect on oxidation efficiency was also studied 
at pH 6.6 and 8.6. Finally, pharmaceutical oxidation in real surface water was studied to 
investigate the effects of sample matrix on reaction efficiency. 
2. EXPERIMENTAL 
2.1 Selection of pharmaceutical standards and reagents 
Total of eight pharmaceuticals were chosen for the oxidation experiments, 
including caffeine, acetaminophen, carbamazepine, sulfamethoxazole, trimethoprim, 
erythromycin, lincomycin, and codeine. This is because our previous occmTence study 
showed these compounds were detected in Missouri natural or drinking water. All 
pharmaceutical standards were obtained from Sigma-Aldrich (St. Louis, MO) except 
lincomycin, which was purchased from MP Biomedicals (Aurora, OH). All other 
treatment chemicals (sodium hypochlorite, sodium dihydrogen phosphate, disodium 
hydrogen phosphate and sodium permanganate) were certified ACS grade and were 
purchased from Sigma-Aldrich (St. Louis, MO). LC-MS grade mobile phase solvents 
(methanol, acetonitrile) were purchased from Fisher Scientific (Fairlawn, NJ, USA). 
Formic acid (MS grade) was obtained from Sigma-Aldrich (St. Louis, MO). 
2.2 Oxidant solution preparations 
Sodium hypochlorite (NaOCl, 5%) served as a source of free chlorine stock 
solution. Laboratory DI water was used to make all dilutions. The NaOCl working 
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solution was stored in an amber glass bottle and wrapped with aluminum foil for 
protection from light. The concentration of free chlorine solution was determined using 
Accuvacs Ampuls from the Hach Company (Loveland, CO, USA) and using the Hach 
DPD Method 8021. The free chlorine concentration was measured before every 
experiment and DI water served as blank. 
Monochloramine stock solution was created from the reaction of sodium 
hypochlorite solution and ammonium chloride solution at the molar ratio of 1:1.05 in pH-
adjusted 5.0 mM phosphate buffer. Excess ammonia at pH >9 (-5%, determined by 
Orion Model9512 Ammonia probe (Thermo-Electron Corporation, Waltham, MA)) was 
maintained during monochloramine solution preparation to prevent the presence of free 
chlorine. Monochloramine concentration was measured by Accuvacs Ampuls with the 
Hach DPD Method 10200 for nitrogen, free ammonia and chloramine (mono). The 
concentration of total chlorine in the monochloramine working solution was also 
measured by Accuvas Ampuls with the Hach DPD Method 8167 to ensure free chlorine 
was indeed absent in the working solution. 
Permanganate stock solution was prepared by dissolving sodium permanganate 
crystals in lab DI water to the desired concentration. The working solution concentration 
was measured by a Cary 50 Cone UV-Visible Spectrophotometer (Varian CO, Australia) 
at 525 nm and lab DI water served as blank. 
Ozone gas was produced from an ozone generator (Model GLS-1 PCI-WEDECO, 
Environmental Technologies, West Caldwell, NJ, USA) with a source of compressed 
oxygen. Nonstop gaseous ozone flow bubbled out from a diffuser into deionized Milli-Q 
water (Millipore, Bierica, MA) to keep the ozone stock solution saturated for immediate 
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use. The concentration of ozone solution was determined using Accuvas Ampuls with the 
Hach Indigo Method 8311 immediately after sampling and lab DI water again served as 
blank. 
2.3 Analysis 
All sample analysis was performed using a triple-quadrupole mass spectrometer 
(Applied Biosystems API 4000Q TRAP) equipped with an Agilent (Palo Alto, CA) 1100 
series HPLC system. The analytical method was the same as in our previous study [28]. 
In summary, 10 111 sample solution was injected onto a Supelco C-18 150x2.1 mm 
column from Sigma-Aldrich (St. Louis, MO) for the separation of the analytes at room 
temperature. The binary gradient for separation of the selected compounds consisted of 
0.1% formic acid (v/v) in both water and acetonitrile at a flow rate of 0.25 mL!min. 
Multiple reaction monitor (MRM) in positive electrospray ionization (ESI) mode was 
used to analyze the selected pharmaceuticals. Mass calibration was performed before 
each study. Compound-dependent parameters and source-dependent parameters were 
optimized in the mass spectrometer individually. Two pairs of ion transitions were 
chosen in the optimization process. The ion transition with the most intense signal was 
selected to be the quantification ion pair of the corresponding compound, while the ion 
transition with the second highest signal was selected to be the confirmer ion pair of the 
corresponding compound. 
Instrument detection limits (IDLs) were determined by performing injections of 
each individual pharmaceutical at a low concentration (with a signal to noise ratio of 
approximately 3-5:1) for 10 consecutive times with the column. The method detection 
limits (MDLs) of pharmaceutical compounds in both lab DI water and natural surface 
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water were determined separately, and was calculated by multiplying the standard 
deviation(s) of the replicate analyses by the appropriate students' t value at 99 percent 
confidence level with nine degrees of freedom. The method reporting levels (MRLs) of 
all selected pharmaceuticals in this study were chosen as 0.25 ng/ml except for 
acetaminophen, which was I ng/ml. 
2.4 Treatments 
Phosphate buffer systems were chosen to carry out the oxidation experiments. 
Phosphate buffer (5 mM NaH2P04 and Na2HP04) were prepared in lab DI water, and 
adjusted to pH 6.6 and 8.6, respectively using different ratios. Natural water samples 
were collected from Missouri River and Shuman Lake (Rolla, MO), and were for 
immediate use. Both natural water samples were filtered using 0.45-~m nylon filters 
(Whatman, England), followed by the addition of solid phosphate salts and adjustment of 
pH to 8.6. 
The concentrations of working pharmaceutical solutions were 5 ~giL (except for 
acetaminophen, which was 20 ~g/L), which were prepared in both buffer systems. Each 
working pharmaceutical solution was transferred to an amber glass reactor for initial 
concentration determination. Oxidations were initiated by spiking an appropriate amount 
of each oxidant solution to the working pharmaceutical solutions at ambient temperature. 
The concentrations of free chlorine, permanganate, ozone and monochloramine were I, 1, 
1.5, and 3 mg/L, respectively. The reactor was rapidly mixed and put on an orbital shaker 
for reaction. Samples were taken at 0, 3, 30, 60, 100, 150, and 300 min (samples were 
taken at 0, 2, 5, 10, 15, 30, and 40 min. in ozone oxidation experiment) for analysis to 
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determine the concentrations of target pharmaceutical compounds and the oxidants. All 
the experiments were conducted at room temperature of25°C. All reactors were wrapped 
in aluminum foil to prevent any light disturbance during the experiments. Each 
experiment was conducted in duplicate for accuracy control and calculation of standard 
deviation. 
For the PAC removal experiment, the pharmaceutical working solutions were 
prepared in amber glass reactors at the same concentrations used in the oxidation 
experiments. Then 2 mg/L Norit HOB PAC was spiked to initiate the reaction. The 
solution was mixed up to 24 hrs for the reaction to take place. Samples were analyzed at 
1, 2, 4, and 24 hours. 
3. RESULTS AND DISCUSSION 
3.1 Free chlorine oxidation 
The reactivity of selected compounds with free chlorine in two pH buffer systems 
was shown in Figure 1. Error bars on the data points indicated the reproducibility of the 
measurements of pharmaceuticals in the study. Under specified oxidation conditions, 
both caffeine and carbamazepine were resistant to free chlorine in both pHs. At pH 8.6, 
most pharmaceuticals were reactive with free chlorine (OCl-) and >85% removed at aCT 
value of 24 mg·min!L. Showing high reactivity, all of lincomycin, 70% of 
sulfamamethoxazole and 50% of trimetethroprim were removed at a CT value of 3 
mg·min!L at pH 8.6. At pH 6.6, four pharmaceutical compounds were >90% removed at 
a CT value of 24 mg·min!L. Erythromycin and acetaminophen were 90% removed at the 
CT value of 198 mg·min!L. By comparing the results in two different pH systems, it was 
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found that the oxidation of erythromycin and acetaminophen by free chlorine were a little 
faster at pH 8.6 than pH 6.6. Most pharmaceuticals can be removed at the CT value of 
200 mg·min/L at both pHs. 
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Figure 1. The oxidation of selected pharmaceutical compounds by free chlorine in (a) pH 
8.6 buffer and (b) pH 6.6 buffer. 
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The removal experiments were also carried out in the lake water for comparison 
(Figure 2). The concentration of free chlorine decreased faster in real water oxidation 
than lab DI water. This indicated that the real water matrix had a strong competition with 
the selected pharmaceutical compounds for free chlorine oxidant. Most pharmaceuticals 
can still be removed during the oxidation study, but the rate was much slower than that in 
the lab DI water. The results showed that the oxidation trends for all of the studied 
pharmaceutical compounds in lake water were the same as those in the lab DI water. 
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Figure 2. The concentration of detected pharmaceutical compounds in free chlorine 
oxidation experiment in pH 8.6 lake water. 
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3.2 Permanganate oxidation 
Permanganate is a highly reactive oxidant and widely used in the water treatment 
facilities. When it functions as an oxidizing agent, sodium pennanganate (Mn04-, Mn 
VII) is reduced to manganese dioxide (Mn02, Mn IV). Figure 3. showed the oxidation 
results of the target pharmaceutical compounds using permanganate as an oxidant in two 
different pH buffer systems. It was found that the reactivity was not pH dependent. 
Acetaminophen was degraded rapidly at both pHs in the presence of petmanganate. 
Codeine and carbamazepine were also reacted readily with pennanganate. Both 
compounds were reacted at a CT value of 27 mg·min/L. The reactivity of lincomycin 
with permanganate was slow. It was 90% oxidized by permanganate at a CT value of 
250 mg·min/L in pH 8.6, but only 30% was oxidized at pH 6.6 at a similar CT value. All 
other compounds were not reactive to permanganate. Trimethoprim, erythromycin and 
sulfamamethoxazole were removed 20-50% at aCT value of250 mg·min/L at both pHs. 
Same oxidation experiments were also carried out in Missouri River water for 
comparison (Figure 4). The concentration pattern of permanganate was the same as that 
of the oxidation study in DI water. This indicated that the sample matrix (organic matters) 
in the surface water was not competitive with selected pharmaceutical compounds in the 
permanganate oxidation system, but did interfere with the oxidation of pharmaceutical 
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Figure 3. The oxidation of selected pharmaceutical compounds by permanganate in (a) 
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Figure 4. The oxidation of selected pharmaceutical compounds by permanganate in pH 
8.6 Missouri river water. 
3.3 Ozone oxidation 
56 
The reactivity of selected compounds with ozone (1 .5 mg/L) in two different pH 
buffer systems was shown in Figure 5. The oxidation of the selected pharmaceuticals by 
ozone was quite rapid and completed in about 2 min. In addition, ozone was unstable in 
aqueous solution. Due to these two reasons, the concentration of ozone was barely 
detected after 2 min. As a result, a CT curve was not used in the ozone oxidation studies. 
The concentration of each pharmaceutical compound did not decrease significantly after 
two minutes, which indicated that the soluble ozone in the oxidation system was entirely 
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reacted until ozone was totally decomposed (about 2 min). A higher concentration of 
ozone was required to completely remove the pharmaceuticals at the experimental 
concentrations. The data also showed that ozone oxidation was pH dependent. Since 
ozone was more stable in lower pH, some phmmaceuticals were easier to be oxidized at 
pH 6.6 than 8.6. In particular, acetaminophen, licomycin, erythromycin, codeine and 
carbamazepine showed were very reactive with ozone. The oxidation of some 
pharmaceuticals was pH dependent. Carbamazepine, licomycin, codeine, trimetethroprim 
and sulfamamethoxazole showed higher oxidation percentages in pH 6.6 buffer than 
those in pH 8.6 buffer. A greater percentage (-75%) of carbamazepine removal was 
observed in pH 6.6, but only -10% of carbamazepine was removed in pH8.6. 
Acetaminophen and erythromycin did not show strong pH dependence on oxidation 
between the two pHs. The data in Figure 5 also indicated that there was a strong 
competition among the pharmaceuticals for ozone oxidation system. Carbamazepine, 
erythromycin and licomycin appeared more reactive with ozone compared to other 
pharmaceuticals. Caffeine showed very little change over time. This data may still be in 
agreement with the literature when the following factors are considered: in our study, 
higher PPCP concentrations were used, half or less of the literature ozone concentration 
was used, reactions were performed at approximately 16 oc higher than the literature 
work (thus decreasing ozone solubility), and higher pH buffer conditions were used. As 
our pH study showed that greater reaction efficiency was observed at lower pH, it is 
reasonable that less pharmaceuticals were oxidized in our 6.6 and 8.6 pH systems than 
the literature's pH 5 system. Finally, the ozone in our experiment was below the detection 
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limit after 2 min. , while the experiment in the literature repotied 0.2-0.3 mg/L of ozone 
after 3 min (Snyder et al. 2006; Westerhoff et al. 2005). 
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Figure 5. The oxidation of selected pharmaceutical compounds by ozone in (a) pH 8.6 
buffer and (b) pH 6.6 buffer. 
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3.4 Monoclzloramine oxidation 
Monochloramine is a relatively stable compound and is becoming an increasingly 
popular alternative disinfectant to chlorine in municipal drinking water systems because 
of its stability in distribution system. The reactivity of selected pharmaceutical 
compounds with monochloramine at two different pH buffer systems was shown in 
Figure 6. Data were collected after exposures of 0, 2, 30, 60, 120, 240 and 360 minutes. 
All compounds were very resistant to monochloramine except lincomycin. No significant 
oxidation was observed following exposure of monochloramine up to 1000 mg·min/L. 
The results demonstrated that monochloramine at a typical drinking water treatment 
dosage was not so effective to remove these selected pharmaceuticals as free chlorine due 
to the lower oxidation potential of monochloramine. This also indicated that fewer 
pharmaceutical degradates might be generated when monochloramine was used as a 
disinfectant in municipal drinking water systems. 
3.5 Removal of pharmaceutical compounds with powered active carbon 
The removal of selected pharmaceuticals by powdered activate carbon was also 
investigated in DI water and in surface water. Figure 7 showed the results of 2 mg/L 
Norit HDB PAC to remove the selected pharmaceuticals in DI water in two different 
pHs. Even though these compounds were partially removed by PAC in a 24 h 
experiment, the removal efficiency was compound dependent. The 24 h contact time was 
used because it was close to the equilibrium condition for the PAC. Erythromycin and 
trimetethroprim showed approximately 70% and 50% removal at the equilibrium time, 
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and all other pharmaceuticals showed about 20-30% removal at the selected conditions. 




T T T I 1 --- J ---1 --T T.--- 1 -






- Erythromycin - lincomycin - Tri m ethoprim .. 
I! 
1: - Sul famamethoxazole - Acetam i nophen Carbam azepine 
el 10 -a 
--Caffeine Co de ine MCA(as Cl2)/ mcl-1 8 
-=- -~ 
5 = = --= 1 -==. == :£~- = :L _ ... 




0 .0 9 .0 89.4 178.4 354.9 705 .9 1056.0 











.. - Erythromyci n - Li ncomycin - Tr i m ethoprim 
,Q 
.. 
I! - sul famamethoxazo le - At:etam inophen _. Carbamazapine 
.. 
II: Caffe i ne Codeine ~ MCA(as Ci 2 )/ m&L-1 ~ 10 
8 
= 5 




0 .0 8 .9 87.8 175.2 349.1 694.7 1039.7 
CT (mg/l min) 
Figure 6. The oxidation of selected pharmaceutical compounds by monochloramine in (a) 
pH 8.6 buffer and (b) pH 6.6 buffer. 
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The PAC removal experiment was also carried out in Missouri River water to 
investigate the effect of sample matrices (Figure 8). The data showed that most 
pharmaceuticals were not removed from the river water at the selected dosage of PAC 
even when the equilibrium was reached. This comparison indicated that the sample 
matrix played an important role in the pharmaceutical removal in natural surface water. 
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Figure 8. The concentration of detected pharmaceutical compounds in PAC removal 
experiment in pH 8.6 Missouri river water matrix. 
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4. CONCLUSIONS 
Thorough investigation of pharmaceutical removal using different oxidants was 
performed. The oxidation removal of selected pharmaceutical compounds varied 
significantly in different oxidation processes. In comparison, chlorination was highly 
effective in the elimination of the selected pharmaceuticals. Sample matrix and pH 
caused notable differences in oxidation efficiency. Permanganate was also effective to 
decompose some pharmaceuticals. Even though different removal efficiency was 
observed between two pHs, sample matrix in sutface water did not change the oxidation 
efficiency. Ozone was a fast oxidizer but very unstable. The ozone oxidation was 
completed in about 2 min under the selected conditions. Chloramination was mostly 
ineffective in oxidation removal of all the studied pharmaceuticals at the typical 
disinfection dose (3 mg/L). Parallel studies in different water matrices indicated that the 
oxidations proceeded similarly but with a relatively slower rate in the surface water due 
to the effect of matrices. The results of this work have shown that some oxidation 
systems may be useful in eliminating some of the PPCPs in water treatment facilities. 
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Total ion chromatogram of pharmaceutical compounds in negative ionization mode. 
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The pharmaceuticals levels in Reservoir from February to June 2009 (ng/L). 
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Investigation of Oxidative Degradation of Molinate 
in Various Oxidation Treatment Systems by Using liquid chromatography- tandem 
mass spectrometry 
ABSTRACT 
Thiocarbamate pesticides, which are widely used in agriculture, have attracted 
considerable attention because of their impact on people's health and adverse effect on 
environmental safety. In this study, the removal efficiency of molinate by various 
oxidants and identification of the de gradate of molinate in water at different oxidation 
treatment conditions were investigated using LC-MS/MS. The oxidants tested were, free 
chlorine (FC), monochloroamine (MCA), UV radiation (UV), chlorine dioxide (Cl02), 
permanganate (Mn04-), ozone (03), and hydrogen peroxide (H202). Hexahydro-1-H-
azepane-1-carboxylic acid was detected as being a major degradate of molinate after its 
treatment with free chlorine and ozone, while no degradates were present after treatment 
by other oxidants. Kinetic results for a typical free chlorine degradation indicated that the 
reaction of molinate with free chlorine was extremely fast. Hexahydro-1-H-azepane-1-
carboxylic acid, the molinate degradate, showed more resistant to free chlorine in the 
same treatment. A possible degradation pathway of molinate is proposed. 
Keywords: 




Molinate (S-ethyl perhydroazepane-1-carbothioate) is a herbicide, in the 
thiocarbamate chemical class, that controls the water weeds in rice paddies around the 
world. Molinate is one ofthe most welcome herbicides in the rice plant area because it is 
much easier to use than other herbicides. In California, over 95% of acreage was treated 
with molinate in 1989, and approximately 60% of that acreage was still being treated 
with molinate in 1997 [1]. In 1997, the amount of molinate applied during the 6-week 
spring period in California totalled 1.3 million pounds [2]. This large amount of molinate 
usage has generated a lot of concern about the potential adverse impact on human health 
and environmental safety. Since the 1970s, several toxicity studies have been conducted 
to prove that molinate is toxic to the reproductive systems ofrats and even has an effect 
on the ovaries of these rodents [3]. These studies have led to more extensive 
investigations of other organs and systems that found that molinate is toxic to the nervous 
system and is possibly carcinogenic as well [4]. 
Due to the harmful effects of molinate on animals and its potential adverse effect 
on human, some studies have been conducted to determine the occmTence of molinate in 
the environment and its degradation pathway under ce11ain systems. Several gas 
chromatographic methods have been developed to study the occmTence of molinate in a 
variety of environmental samples [5-8]. The photodegradation ofmolinate in water has 
also been investigated, and 4-keto derivative was found to be the predominant degradate 
[9, 1 0]. The degradation pathway of molinate in plants has also been repmted, and 
several degradates have been identified [11], including lH-Azepane, 1-
[ ( ethylsulfinyl)carbonyl]hexahydro-, 1 H-Azepane-1-carbothioic acid, hexahydro-4-
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hydroxy-, S-ethyl ester, 1H-Azepane-1-carbothioic acid, hexahydro-2-oxo-, S-ethyl ester, 
1 H-Azepane-1-carbothioic acid, hexahydro-4-oxo-, S-ethyl ester. The major metabolic 
pathway of molinate degradation in laboratory rats has involved sulfoxidation and 
conjugation with glutathione [12]. The oxidative metabolism ofmolinate in humans was 
mainly mediated by cytochrome P-450 [13]. The pathway of mineralization of molinate 
by a mixed culture of five bacteria was also recently reported [14]. However, information 
about the oxidation pathway of molinate in the water treatment process is very limited. 
Several occurrence studies have shown that high concentrations of molinate were 
detected in different water samples, including four rivers in Japan [6], rain samples from 
Greece [15], and ground and surface waters from several countries [15-19]. All of the 
occurrence studies indicated that molinate contamination exists in natural water systems. 
Therefore, assessments of the removal of molinate by various oxidation systems become 
very impm1ant in providing information of value for drinking water and waste water 
treatment processes. However, no extensive study has been conducted to date to provide 
such information. 
In this paper, the efficiency of molinate removal under different treatment 
conditions, using various oxidant systems, was investigated and quantified. A new 
oxidation de gradate was observed and confirmed by liquid chromatography- UV /mass 
spectrometry (LC-UV/MS) and liquid chromatography- tandem mass spectrometry (LC-
MS/MS). This finding can be impot1ant because the disinfection process could make the 
situation even worse due to the formation of more toxic degradation products. Based on 
our study, a predicted degradation mechanism ofmolinate in the oxidation processes is 
proposed. 
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MATERIALS AND METHODS 
Reagents and chemicals. Molinate (99.0% CAS: 2212-67-1), formic acid (96%, 
ACS grade), sodium hypochlorite solution (available chlorine 3 4%), and hydrogen 
peroxide solution (30%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Methanol (optimal grade), acetonitrile (HPLC grade), ammonium chloride (certified ACS, 
99.5%), sodium phosphate (dibasic, 99%), and potassium permanganate (ACS reagent) 
were purchased from Fisher Scientific (Pittsburgh, P A, USA). 
A molinate stock solution was prepared in methanol at a concentration of2643.3 
11g mL-1, and then diluted to 1000 11g mL-1, as stock solution 2. Both stock solutions were 
stored in a freezer during the experiment. Further spike solutions were prepared from 
stock solution 2, depending on the pmticular experiment. All experiments were carried 
out at room temperature (25 ± 1 °C). The pH values were measured by an Accumet 
AccuCap combination pH electrode from Fisher Scientific (Pittsburgh, P A). 
Instruments. The HPLC-UV /MS analysis of molinate and its oxidation de gradate 
were carried out by the Hitachi M-8000 LC/3DQMS system, coupled with a UV detector 
and an electrospray ion source. A Perkin Elmer series 200 HPLC coupled with an 
Applied Biosystem API 4000 Q triple quadrupole mass spectrometer was used to confirm 
the structure of an oxidation de gradate of molinate. A Phenomenex Synergy 4u Fusion-
RP HPLC column (150 x 3.0 mm i.d., 4 11m) was used to separate molinate and its 
degradate with a typical flow rate of0.5 mL min-1 during the whole experiment. Mobile 
phase A was composed of water with 0.1% formic acid, while mobile phase B was 
acetonitrile. The HPLC separation procedure included two parts: ( 1) cln·omatographic 
condition one was for the molinate parent with an isocratic composition of mobile phase 
A to B at 55 to 45%, and (2) chromatographic condition two was for the degradate with 
an isocratic composition of mobile phase A to B at 80 to 20%. 
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The Hitachi electrospray ion source parameters were optimized as follows: ESI 
probe voltage, focus voltage, drift voltage, and detector voltage were set at 4000, 25, 30 
and 450 V, respectively. The assistant gas heater temperature, desolvator temperature, 
aperture 1 temperature, and aperture 2 temperature were set at 180,200, 160, and 120°C 
respectively. Nitrogen sheath gas was set at 300 kPa. 
For the MS/MS study of molinate and its de gradate by an API 4000 Q trap triple-
quadrupole mass spectrometer, a positive ion electrospray mode was chosen for the 
ionisation source and a Multiple Reaction Monitoring (MRM) scan was applied. The first 
quadrupole was used to monitor the precursor ion (M + Ht at m/z 188 amu, and the third 
quadrupole was used to monitor the quantification ion (M +H)+ at m/z 126 amu and the 
identification ion at m/z 83. 'Unit' resolution was set for both Q1 and Q3 during the 
whole experiment and the dwell time for each MRM scan was 150 ms. The ion source 
temperature was set at 700°C with an ion spray voltage of 4000 V. The nebulizer gas, 
auxiliary gas, and curtain gas were 413, 551, and 206 kPa, respectively. The declustering 
potential and entrance potential were maintained at 46 and 10 V. The collision energy 
and collision cell exit potential were set at 21 and 8 V for the quantification ion m/z 126 
and 25 and 6 V for the identification ion m/z 83.1 respectively. 
Free chlorine (FC) oxidation system. Free chlorine solutions of desired 
concentrations were diluted from a sodium hypochlorite solution and stored in the dark 
for later use. Accuvacs, obtained from the Hach Co. (Loveland, CO, USA), with the Hach 
DPD Method 8021 were used to measure the concentration of free chlorine every time 
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before use. A 500-J.tL aliquot ofmolinate stock solution (10 mg mL-1 in methanol) was 
spiked into a 100-mL Pyrex glass bottle (served as a reactor). Methanol was evaporated 
in the hood at room temperature, followed by the addition of 49 mL of Mill-Q water. 
After thorough mixing using a vmtex, 1-mL aliquot offree chlorine (5 mg mL-1 in Mill-
Q water) was spiked into the reactor to allow both the molinate and the free chlorine to 
reach a I 0 mg L-1 concentration. The solution was mixed well with the vo11ex again. The 
bottle was wrapped with aluminium foil and kept in the dark. The mixed sample was 
shaken for 2 hr on an orbital shaker for a reaction, followed by an injection to the HPLC 
system coupled with UV and mass spectrometer detectors. 
The concentration-time experiment was conducted by spiking a desired free 
chlorine stock solution into the molinate in a reactor to reach an initial concentration of 
1.61 mg L-1 for the free chlorine and 3.69 mg L-1 for the molinate. This reactor was 
wrapped with aluminium foil and shaken on an orbital shaker. Samples were collected 
and quenched using ascorbic acid before being injected into the HPLC-UV /MS system 
for analysis at intervals of 0, 10, 20, 30 and 40 min. 
Ozone oxidation system. Gaseous ozone was generated from an ozone generator 
(Model GLS-1 PCI-WEDECO, Environmental Technologies, West Caldwell, NJ, USA) 
using compressed oxygen. Ozone gas was bubbled out from a diffuser into Mill-Q water 
to form a saturated ozone solution for immediate use. Concentration of the ozone solution 
was measured by a Cary 50 Cone UV-Visible Spectrophotometer (Varian CO, Australia) 
at 260 nm immediately after sampling, with the Mill-Q water served as a blank. Ozone 
oxidation of the molinate was performed in both a pH 6.6 and a pH 8.6 NaH2P04 buffer 
with three different ozone dosages. After the molinate was spiked into the reactors, 
different volumes of the saturated ozone solution were added into these three reactors. 
The final concentrations were 21.1 mg L-1, 15.8 mg L-1, and 10.5 mg L-1 for the ozone 
and 10 mg L -I for the molinate. This reaction lasted for 4 lu on the orbital shaker, 
followed by injection into the HPLC system coupled with UV and mass spectrometer 
detectors. 
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Chlorine dioxide (Cl02), monochloroamine (MCA), permanganate (Mn04-) and 
hydrogen peroxide (H202) oxidation systems. Gaseous chlorine dioxide was generated 
from a CDG Bench Scale chlorine dioxide generator by solid sodium chlorite (CDG, 
Bethlehem, PA). Chlorine dioxide gas, that was bubbled out from a diffuser into Mill-Q 
water to form a saturated chlorine dioxide solution, was stored in the dark for later use. 
The concentration of the chlorine dioxide solution was measured at 359 nm by a Cary 50 
Cone UV-Visible Spectrophotometer (Varian CO, Australia) every time before use. 
Monoch1oramine was created from the reaction of the sodium hypochlorite 
solution and the ammonium chloride solution, with a molar ratio of I : 1.05 [20]. During 
the reaction, the pH value was controlled above 9 using pre-adjusted phosphate-buffered 
Mill-Q water. The final stock solution had 5% excess ammonia, so there was no free 
chlorine in the solution. The concentration of the monochloramine stock solution was 
measured by Accuvas with the Hach DPD Method 10200 for nitrogen, free ammonia, and 
chloramine (mono). 
Proper amounts of potassium permanganate solid crystal were directly dissolved 
in Mill-Q water and then diluted to desired concentrations. The concentration of the 
potassium permanganate was measured by Accuvacs with the Hach DPD Method 8167. 
86 
An oxidation reaction was started by spiking a proper amount of the oxidant stock 
solution to reactors of the molinate working solution to reach a final concentration of 10 
mg L-1 for both the oxidant (3% for H202) and the molinate. The reactions were stopped 
after 4 hr on an orbital shaker, followed by injection into the HPLC-UV/MS system. 
Ultraviolet radiation (UV) oxidation system. UV radiation was generated by a 
254-nm Pen Ray 1 W low-pressure mercury-vapor lamp (Model 90-0004-01, UVP Inc., 
Upland, CA). The diameter of this lamp was 0.9 em and the length was 9 em. All non-
submerged parts of the lamp were covered by Teflon tape to prevent radiation from the 
sample liquid. Four identical amble glass vials, with a diameter of I. 9 em, served as 
reactors. Experiments were carried out by placing a lamp in the middle of the vials which 
contained 5 mL of2 mg L-1 molinate in NaH2P04 buffer for 2, 25, 45, and 90s. A small 
stirring bar was put in each vial to thoroughly mix the sample buffer during the whole 
exposure process. The experimental dosage was calculated to make certain that the 
fmthest point from the lamp receiveed the desired dosage. In this study, the UV dosages 
were from 134-6030 mW•s cm-2• 
RESULTS AND DISCUSSION 
HPLC-UV!MS ofmolinate and identification of its degradate. A chromatogram of 
molinate is shown in Fig. I a, under chromatographic condition one, and the mass 
spectrum of the molinate standard shows that the mass to charge ratio (m/z) of molinate 
was 188 (Fig. I b). After the molinate standard was oxidised by various oxidants, the 
mixture that contained molinate and its degradate was injected into the HPLC-UV/MS 
system for analysis. An unknown degradate was detected after oxidation by free chlorine 
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and ozone. A new chromatographic condition (condition two) was then developed to 
separate the molinate and its degradate (as shown in Fig. 2a, b under chromatographic 
condition two). Hitachi ion trap HPLC-MS was used to identify the degradate of molinate 
with a mass to charge ratio of 144. The mass spectra of the degradate fi"Om the free 
chlorine oxidation system and the ozone oxidation system were identical (Fig. 2c). Based 
on the total ion chromatogram and mass spectrum of free chlorine and ozone oxidation 
degradate ofmolinate, the structure of the oxidation degradate ofmolinate was proposed 
to be 1 H-Azepane-1-carboxylic acid, hexahydro-. This oxidation degradate was much 
more stable to free chlorine than its parent. Unfortunately, the standard of this oxidation 
degradate was not commercially available for fi.uther identification. 
An AP14000 Q-trap LC triple-quadrupole mass spectrometer, with a Turbo Spray 
ionisation source, was used to confirm the oxidation de gradate of molinate. Two ion pairs 
were chosen for the molinate parent: 188/126 was for the quantification and 188/83 was 
for identification. The detection limit was 0.10 mg L-1. After injection of a sample 
oxidation mixture into the LC-MS/MS, a strong signal at m/z 143.8 was observed in the 
mass spectrum, which indicated the molinate oxidation degradate. This result matched 
the data from the Hitachi ion trap HPLC-MS (as shown in Fig. 3). 
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Figure 1. (a) LC- UV chromatograms of blank, control (standard molinate), and 
oxidation degradate of molinate under chromatographic condition 1. (b) Mass spectrum 
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Figure 2. (a) LC- UV chromatograms of blank, control (standard molinate), and 
oxidation de gradate of molinate under chromatographic condition 2. (b) Total ion 
chromatograms of blank, control (standard molinate) and oxidation degradate of molinate 
under clu·omatographic condition 2. (c) Mass spectrum for oxidation degradate of 
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Figure 3. (a) Mass spectrum of the degradation product of molinate by using API 4000 
triple quadrupole mass spectrometer. (b) Product ion scans of the degradation product 
using API 4000 triple quadrupole mass spectrometer. 
Quantitative results of the oxidation of molinate using several oxidation systems. 
The quantitative studies depicted in Table 1 show that the percentage of molinate removed 
by various oxidants had changed significantly. The data demonstrated that molinate can 
only be oxidized by free chlorine and ozone, while other oxidants do not show significant 
removal (£ 7%). The reaction of molinate with free chlorine was quite fast; 10 mg L - t of 
molinate were totally removed by 10 mg L - I of free chlorine within two hours. UV 
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radiation did not show any significant removal under a pH= 8.6 condition, with a dosage 
range of 134-6030 mW•s cm-2. 
Based on the data in Table l, ozone oxidation of molinate was pH dependent; 
molinate was easier to be oxidised and removed in acidic pH rather than an alkaline 
condition. The data also demonstrated that removal of molinate by ozone was not 
significantly dosage dependent. It showed that the percentages of removals of molinate 
at pH 8.6 for 4 hr were about the same as by using a low dose, a medium dose, and a high 
dose of ozone. 
Experimental results of a concentration-time study of the free chlorine oxidation 
system. Due to the strong oxidation ability of free chlorine to molinate, a concentration-
time experiment was necessary to determine the detailed degradation process of molinate 
by free chlorine. Since the standard of the oxidation de gradate was not available, and 
only one major degradate was observed in the LC-UV chromatogram and total ion 
chromatogram in LC-MS, it was assumed that molinate was stoichiometrically oxidized 
to only one oxidation degradate in 21u·s. The reason for this assumption was that 
molinate was undetectable after 2 lu·s and the peak area of molinate de gradate remained 
constant at about the same peak area as that of molinate. It was also found that the free 
chlorine oxidation of molinate was fast and its oxidation degrade was more stable than 
that of its parent compound. Therefore, after appropriate amounts of free chlorine were 
spiked to the 2, 3, 4, and 5 mg L-1 of the molinate standard solution, and followed by a 2 
hr reaction, a pseudo-calibration curve of molinate de gradate was made by measuring the 
peak area of the molinate degradate. In this case, the concentration of the molinate 
de gradate we measured served as the real concentration of the oxidation de gradate 
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because of its molecular stability. The sum of molarities of molinate and the oxidation 
degradate in the experiment (as shown in Fig. 4) was >87% of the spiked concentration of 
molinate in the 40 min oxidation experiment. It was found that at each time interval that 
was studied, the sum of the measured molinate concentration and the calculated 
concentration of the molinate degradate was almost the same. This result, combined with 
the linear curve of the molinate degradate, indicated that our assumption was correct. The 
trend line also demonstrated that molinate was quickly oxidized in the first 10 min, and 
then reached an equilibrium state with the degradate, as significant drop of free chlorine 
concentration. 
Table 1. Quantitative results of molinate oxidation using different oxidants 
Reaction Conditions 
High ozone dosage (21.1 mg/L), pH6.6, 4 h 
Medium ozone dosage (15.8 mg/L), pH6.6, 4 h 
Low ozone dosage (10.5 mg/L), pH6.6, 4 h 
High ozone dosage (21.1 mg/L), pH8.6, 4 h 
Medium ozone dosage (15.8 mg/L), pH8.6, 4 h 
Low ozone dosage (10.5 mg/L), pH8.6, 4 h 
Free chlorine (10 mg/L), 2 h 
MCA (10 mg/L), 4 h 
Cl02 (10 mg/L), 4 h 
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